Powerful reduction in severe exacerbations through Week 241,a

up to
81%
reduction
in severe exacerbations
through Week 24
Rate ratio: 0.19 (95% CI: 0.07, 0.56)1,a

Up to 81% reduction in severe exacerbationsa through Week 24 with DUPIXENT 300 mg Q2W + SOC (n=64) vs
placebo + SOC (n=68) (0.20 vs 1.04; rate ratio: 0.19 [95% CI: 0.07, 0.56]) (baseline blood EOS ≥300 cells/µL,
DRI12544, secondary endpoint).1

Up to 81% reduction in severe exacerbationsa through Week 24 with DUPIXENT 300 mg Q2W + SOC (n=64) vs
placebo + SOC (n=68) (0.20 vs 1.04; rate ratio: 0.19 [95% CI: 0.07, 0.56]) (baseline blood EOS ≥300 cells/µL,
DRI12544, secondary endpoint).1

QUEST primary endpoint results (ITT population)1,2

  • 48% reduction in severe exacerbations at Week 52 with DUPIXENT 200 mg Q2W + SOC (n=631) vs placebo + SOC (n=317) (rate ratio: 0.52 [95% CI: 0.41, 0.66])
  • 46% reduction in severe exacerbations at Week 52 with DUPIXENT 300 mg Q2W + SOC (n=633) vs placebo + SOC (n=321) (rate ratio: 0.54 [95% CI: 0.43, 0.68])

aDRI12544/QUEST: Severe exacerbations were defined as deterioration of asthma requiring the use of SCS for at least 3 days or hospitalization or ED visit due to asthma that required SCS.1

DUPIXENT eliminated severe exacerbations in a majority of patients for up to 3 years4,b

97%
of patients
did not have an exacerbation requiring hospitalization or ED visit
in 3 years3,b
  • Patients rolled over from DRI12544 and QUEST treated with DUPIXENT 300 mg Q2W + SOC (n=2062) during
    the second and third years in the OLE period (TRAVERSE OLE, secondary endpoint)c,d
ZERO
exacerbations
in 89% of patients in Year 34,b

Zero EXACERBATIONSb IN 89% OF PATIENTS FROM QUEST IN YEAR 34

(Weeks 48-96) when treated with DUPIXENT 200 mg/300 mg Q2W + SOC (n=816) for 52 weeks in
QUEST and continued with DUPIXENT 300 mg Q2W + SOC in the OLE period (TRAVERSE OLE, other
endpoint).

  • 79.5% of patients rolled over from DRI12544 (n=396) experienced 0 exacerbations during
    Weeks 48-964
  • 74% of patients rolled over from DRI12544 and QUEST (n=2062) experienced
    0 exacerbations over ~3 years of treatment with DUPIXENT3

Results are descriptive. Definitive conclusions cannot be made.

Data were not multiplicity controlled and there are limitations associated with open-label study design, including lack of comparator arm, decreasing sample size, and potential continued involvement of responders and attrition of nonresponders.

bTRAVERSE OLE: Severe asthma exacerbations were defined as requiring SCS for ≥3 days, hospitalization, or ED visit.4

cAnalysis includes DRI12544 and QUEST patients enrolled in TRAVERSE.3

dOf the 542 patients who experienced at least 1 severe asthma exacerbation, 66 (3.2% of the overall study population) had an exacerbation that required hospitalization or ED visit during the TRAVERSE study period (unadjusted annualized event rate of 0.027).3

DUPIXENT reduced severe exacerbations across EOS levels at Week 523

PATIENTS WITH ELEVATED EOS (QUEST, PRESPECIFIED SUBGROUP ANALYSIS)1,3

Reductions in severe exacerbations when added to SOC. No statistically significant differences were observed during the 52-week treatment period in patients with baseline blood EOS <150 cells/μL taking DUPIXENT 200 mg Q2W or 300 mg Q2W + SOC and in the ≥150 to <300 cells/μL EOS subgroup treated with DUPIXENT 200 mg Q2W + SOC vs matching placebo + SOC.1,3

DUPIXENT trials enrolled patients with EOS levels up to 1500 cells/μL.1

eSecondary endpoint.3

PATIENTS WITH ELEVATED EOS + ALLERGIC ASTHMA (QUEST, POST HOC ANALYSIS)1,3

Results are descriptive. Definitive conclusions cannot be made as this was a post-hoc analysis. There are limitations on sample size and data
were not multiplicity controlled.

Allergic asthma was defined as total serum IgE ≥30 IU/mL + ≥1 positive perennial-aeroallergen–specific IgE ≥0.35 kU/L at baseline.5

ED, emergency department; EOS, eosinophils; ICS, inhaled corticosteroid; OLE, open-label extension; Q2W, once every 2 weeks; SCS, systemic corticosteroid; SOC, standard of care.